QuarterHawk — Equity ResearchQuarterHawk — Equity Research

Fresenius Medical Care AG & Co. KGaA (FMS)

Healthcare

No action
Fundamental
3
Sentiment
2
Technical
3

Do Nothing: qualitativeScore is 2 (below the required floor of 3); the strategy requires qualitativeScore >= 3 before any bullish entry, and the shadow branch is unavailable (flag false), so no trade plan is emitted despite a mixed-but-intact chart.

Analysis as of 2026-11-10· more than 2 trading days ago

Company overview

Fresenius Medical Care AG & Co. KGaA provides kidney dialysis treatment and related services globally, operating outpatient clinics and supplying home-based care equipment. It also manufactures and distributes dialysis products and non-dialysis medical devices, and offers specialized medical services.

Fundamental

fair
Fundamental3
Mixed fundamentals

Strong cash generation contrasts with negative earnings momentum and litigation overhangs.

Dialysis leader with strong cash generation and an investment-grade balance sheet, but negative 2026 earnings momentum: third-quarter operating income fell about 19% and per-ADS earnings about 35% year over year amid reimbursement headwinds, returns below the cost of capital and a very large goodwill balance. Valuation is low (mid-teens earnings multiple, roughly 16.6% free-cash-flow yield) and leverage is moderate, so the picture is mixed rather than distressed - a watchlist name rather than a clean buy.

Sentiment

weak
Sentiment2
Bearish sentiment

Media sentiment is mildly negative, with recent downgrades and no positive catalysts.

Dominant near-term driver is adverse: a 2026-11-03 Q3 print that narrowed the 2026 operating-income outlook to the lower half (announced), followed by a 2026-11-09 Barclays downgrade to Underweight on reimbursement pressure (announced). The two-window media-sentiment delta is determinate and flat (baseline polarity_score ≈ −0.13 off 14 scored items → scoring ≈ −0.20 off 2 scored items), the Red-Flag Screen is clean with no severe or moderate flag fired, and because no catalyst carries bullish direction on market-reception grounds the setup is bearish-tilted rather than a genuine two-sided conflict.

Technical

fair
Technical3
Mixed chart

Price action is above short-term averages but lacks a clear directional trend.

Mixed chart read. Price 22.74 sits above the SMA20 (22.47) and SMA50 (22.33) but below the SMA200 (22.91) and below the short stack (EMA9 22.86, WMA9 22.95, DEMA14 23.04, TEMA14 23.18) after a three-session fade from the 23.83 high of 2026-11-05, while holding above EMA21 (22.59) and WMA21 (22.68). Momentum is neutral-to-mildly-positive: RSI14 51.91, Williams %R -45.99, MACD line 0.23 above signal 0.15 and above zero but with the histogram decelerating from 0.16 (11-06) to 0.08 (11-10), and ADX14 11.70 shows no dominant directional trend. Volatility is moderate (ATR14 0.59 = 2.59% of price; StdDev20 0.62). Liquidity is adequate (avgDollarVolume20 about $31.65M; last three regular sessions about $23.7M). The read is a mixed 3/5 — intermediate uptrend intact, longer-term frame capped, nothing broken, nothing confirmed. The trade is nevertheless blocked upstream of the chart: qualitativeScore 2 fails the hard floor of 3 and the shadow branch is not available (flag false), so no trade plan is constructed.

You’re looking at 2026-11-10 — more than 2 trading days ago.

Subscribers saw this then, and see today’s score, verdict and trade plan now.

Not financial advice. For informational and educational purposes only.